Malignant Otitis Externa
Conditions
Brief summary
The study will aim to show that there is a superiority of 18F-FDG PET/CT compared to labeled leukocyte scintigraphy in patients with a malignant otitis externa.
Detailed description
The management of malignant otitis externa (MEO) is a major issue in patients who are often polypathological and fragile. Appropriate antibiotic therapy must be started quickly after the diagnosis is made and followed for a period of at least 6 weeks. Imaging plays a major role in assessing the extent of the infection and especially healing, after 6 weeks of antibiotic therapy. The persistence of an infection at the end of the treatment, observed in imaging, will allow a change of antibiotic line. This study consists in studying in a population affected by an OEM, the performance of PET/CT with 18F-FDG compared to scintigraphy with labeled leukocytes. The usefulness of the latter in the follow-up of the pathology after antibiotic therapy has already been proven in the literature. The study will aim to show that there is a superiority of 18F-FDG PET/CT compared to labeled leukocyte scintigraphy.
Interventions
OTHER18F-FDG PET/CT
Patients who underwent an 18F-FDG PET/CT examination and a labeled leukocyte scintigraphy before and after antibiotic therapy in the case of management of an EO.
Sponsors
Central Hospital, Nancy, France
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* patients with malignant otitis externa who received a 18F-FDG positron emission tomography and a labelled leukocyte scintigraphy
Exclusion criteria
* patients who refuse to have their imaging data used
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 18F-FDG positron emission tomography | one day | measurement of standard uptake value |
| Labeled leukocyte scintigraphy | one day | measurement of standard uptake value |
Countries
France
Outcome results
None listed